Biogen (BIIB) Report 24 -Month Interim Analysis from PRIME

11/7/17

By Seeking Alpha

The following slide deck was published by Biogen Inc. in conjunction with this event.

120

PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease 1 1 1 1 Philipp von Rosenstiel MD , Sarah Gheuens, MD, PhD , Tianle Chen, PhD , John O’Gorman, PhD , Ping Chiao, PhD , Guanfang Wang, PhD , Christian von Hehn, MD, PhD , LeAnne Skordos PharmD , Christoph Hock, MD , 3 Roger M Nitsch, MD , Samantha Budd Haeberlein, PhD , Alfred Sandrock, MD, PhD 1 1 2 3 Biogen, Cambridge, MA, USA; Cytel, Cambridge, MA, USA; Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.

Sponsored -
Agency/Corporate Program

Einhorn Barbarito Frost & Botwinick Elevates Matthew Rheingold to Partner

Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from

Einhorn Barbarito Frost & Botwinick Partners Thomas Snyder and Matheu Nunn Named as Co-Chairs of Firm’s Family/Matrimonial Practice

Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn

McCarter & English’s Mark Anania Named President of the New Jersey Intellectual Property Law Association

Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association

Anthony Chwastyk Joins Cohen Seglias as Senior Counsel

Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the

TRUSTED BY
THESE PARTNERS: